Orexin-A vs Omentin-1
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Orexin-A | Omentin-1 |
|---|---|---|
| Category | Cognitive Enhancement | Diabetes & Metabolic |
| Full Name | Hypocretin-1 (Orexin-A) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 3562 Da | ~35 kDa |
| Half-Life | Minutes to <1 hour | hours |
| Amino Acids | 33 | 313 |
| Typical Dose | Research-only; no validated human dose | No approved human dose; research use only |
| Route | Intracerebroventricular/Intranasal | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 82 |
| Research Status | Pre-clinical | Pre-clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
Omentin-1 Dosing
not established|not established
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.